Merck sells its global clinical chemistry business to DiaSys

Merck KgaA is to sell its global clinical chemistry business to DiaSys Diagnostic Systems, also of Germany. The deal, which is effective from 28 February 2003, does not affect Merck's global clinical microbiology and microscopy/cell diagnostics business. Financial details of the transaction have not been disclosed.

The move is part of Merck's strategy to focus on its core businesses in chemicals. The company will continue manufacturing specific products during a transition period of one year. Employees involved in the transaction will be given new responsibilities within Merck.

DiaSys Diagnostic Systems specialises in in vitro diagnostic systems and has annual sales of more than €10m (US$10.1m). The company is represented in more than 50 countries worldwide and employs 70 people. Merck's Clinical Chemistry business had sales of €7.5m ($7.6m) in 2001. Its main products include standardised diagnostic test kits for diabetes, heart, kidney, inflammation, liver and other diseases as well as controls and calibrators. About a third of the business is located in Germany and 30% in other European countries, while Asia and Latin America each account for around 20%.